CHARLES BUCKMASTER: Open Payments
NPI 1194711382 · FOLEY, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$421 in 22 payments from 12 companies in 2025. Trend: 2023 $815 · 2024 $277 · 2025 $421
Food & beverage: $421
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $96 |
| Otsuka America Pharmaceutical, Inc. | 4 | $73 |
| Indivior Inc. | 2 | $53 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $44 |
| AstraZeneca Pharmaceuticals LP | 2 | $28 |
| Lundbeck LLC | 1 | $23 |
| Novo Nordisk Inc | 1 | $20 |
| GlaxoSmithKline, LLC. | 1 | $20 |
| Almatica Pharma LLC | 1 | $19 |
| Exact Sciences Corporation | 1 | $17 |
Products named: REXULTI, VRAYLAR, SUBLOCADE, CAPLYTA, AIRSUPRA, UBRELVY, Wegovy, TRELEGY ELLIPTA.
Industry payments across AL — which companies pay providers there.
